ADTX · As filed with the SEC
Aditxt income statement, by fiscal year
The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|---|
| REVENUE | |||||
| Sales | 3,195 | 133,985 | 645,176 | 933,715 | 105,034 |
| Cost of goods sold | — | — | — | 766,779 | 77,979 |
| Cost of goods sold | 2,927 | 627,474 | 756,836 | — | — |
| Gross profit (loss) | 268 | (493,489) | (111,660) | 166,936 | 27,055 |
| OPERATING EXPENSES | |||||
| General and administrative expenses $0 and $33,071in stock-based compensation, respectively | 15,974,863 | 16,286,216 | 18,607,142 | 15,985,552 | 22,084,389 |
| Research and development $10,000 and $6,712,663 in stock-based compensation, respectively | 3,194,133 | 10,886,130 | 7,074,339 | 7,268,084 | 5,042,617 |
| Sales and marketing, includes $1,023,045, and $0 in stock-based compensation, respectively | — | — | — | 1,849,460 | 334,977 |
| Impairment on notes receivable | — | — | — | 543,938 | 14,500,000 |
| Sales and marketing $473,311 and $0 in stock-based compensation, respectively | 401,996 | 197,863 | 269,284 | — | — |
| Total operating expenses | 19,570,992 | 27,370,209 | 25,950,765 | 25,647,034 | 41,961,983 |
| NET LOSS FROM OPERATIONS | (19,570,724) | (27,863,698) | (26,062,425) | (25,480,098) | (41,934,928) |
| Interest expense | — | — | — | (753,038) | (93,209) |
| OTHER INCOME (EXPENSE) | |||||
| Interest expense | — | — | (4,195,127) | — | — |
| Interest income | — | — | 10,166 | — | — |
| Other income | — | — | — | 58,960 | — |
| Interest expense | (681,156) | (4,188,725) | — | — | — |
| Interest income | 200,179 | 1,454 | — | 57,348 | 3,101 |
| Amortization of debt discount | (1,706,697) | (3,174,920) | (2,194,773) | (1,533,048) | (1,845,358) |
| Total other expense | — | — | — | (2,169,778) | (4,436,436) |
| Gain on note exchange agreement | — | — | 51,712 | — | (2,500,970) |
| Gain (loss) on note exchange agreement | — | (208,670) | — | — | — |
| Change in fair value of derivative liability | 14,515 | 414,501 | — | — | — |
| Change in fair value of Evofem warrants | 2,806,983 | — | — | — | — |
| Impairment of Evofem F-1 Preferred Stock | (23,766,209) | — | — | — | — |
| Bargain purchase gain from purchase of Evofem convertible notes | 328,071 | — | — | — | — |
| Impairment of fixed assets | (412,005) | — | — | — | — |
| Total other expense | (23,216,319) | (7,156,360) | (6,328,022) | — | — |
| Net loss before income taxes | (42,787,043) | (35,020,058) | (32,390,447) | (27,649,876) | (46,371,364) |
| NET LOSS | (42,787,043) | (35,020,058) | (32,390,447) | — | — |
| Deemed Dividends | (1,387,250) | (5,907,011) | — | — | — |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | (1,072,842) | (573,572) | (9,608) | — | — |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | (43,101,451) | (40,353,497) | (32,380,839) | (27,649,876) | (46,371,364) |
| Implied Dividends | — | — | — | (37,667) | (102,267) |
| Deemed Dividend | — | — | (319,871) | — | — |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | — | — | (32,700,710) | (27,612,199) | (46,269,097) |
| Net loss per share, basic (in Dollars per share) | (1,153.83) | (3,062.51) | (108.15) | (14.89) | (121.18) |
| Net loss per share, diluted (in Dollars per share) | (1,153.83) | (3,062.51) | — | — | — |
| Weighted average number of shares outstanding during the period, basic (in Shares) | 37,355 | 13,177 | 302,356 | 1,854,724 | 381,811 |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | 37,355 | 13,177 | — | — | — |
| COMPREHENSIVE LOSS: | |||||
| Net Loss | (42,787,043) | — | — | — | — |
| Other Comprehensive Loss: | |||||
| Change in valuation of Evofem note | 1,254,170 | — | — | — | — |
| TOTAL COMPREHENSIVE LOSS | (41,532,873) | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.